List of Excipients in Branded Drug RASAGILINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals USA Inc	RASAGILINE	rasagiline	0093-3060	MANNITOL
Teva Pharmaceuticals USA Inc	RASAGILINE	rasagiline	0093-3060	SILICON DIOXIDE
Teva Pharmaceuticals USA Inc	RASAGILINE	rasagiline	0093-3060	STARCH, CORN
Teva Pharmaceuticals USA Inc	RASAGILINE	rasagiline	0093-3060	STEARIC ACID
Teva Pharmaceuticals USA Inc	RASAGILINE	rasagiline	0093-3060	TALC
Teva Pharmaceuticals USA Inc	RASAGILINE	rasagiline	0093-3061	MANNITOL

Generic Drugs Containing RASAGILINE

Company	Ingredient	NDC	Excipient
Torrent Pharmaceuticals Limited	rasagiline	13668-447	MANNITOL
Torrent Pharmaceuticals Limited	rasagiline	13668-447	SILICON DIOXIDE
Torrent Pharmaceuticals Limited	rasagiline	13668-447	STARCH, CORN
Torrent Pharmaceuticals Limited	rasagiline	13668-447	STEARIC ACID
Torrent Pharmaceuticals Limited	rasagiline	13668-447	TALC
NorthStar RxLLC	rasagiline	16714-770	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in RASAGILINE?

# Of NDCs	Excipient
4	ANHYDROUS CITRIC ACID
7	CELLULOSE, MICROCRYSTALLINE
5	CITRIC ACID MONOHYDRATE
1	LACTOSE MONOHYDRATE
5	MANNITOL
12	SILICON DIOXIDE

Rasagiline Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Rasagiline is an established oral monoamine oxidase-B inhibitor used in Parkinson's disease. Its core immediate-release tablet is commercially mature, and U.S. generic entry has reduced the value of basic tablet differentiation. The strongest excipient-driven opportunities are modified oral delivery, improved dose uniformity at the 0.5 mg strength, taste-masked administration, adherence-focused products, and differentiated combination therapies.

The commercial case is stronger for formulation technology than for a new excipient. Rasagiline mesylate is a low-dose small molecule with established regulatory precedent, broad generic competition, and no biosimilar pathway. A successful product would need a clinically meaningful advantage, a low-cost manufacturing process, or a regulatory strategy that supports non-substitution or premium pricing.

What is rasagiline and how is it administered?

Rasagiline mesylate is approved for Parkinson's disease as monotherapy or adjunctive therapy to levodopa. The standard U.S. dosage is 1 mg once daily as monotherapy or adjunctive treatment, with 0.5 mg once daily used in certain patients receiving interacting medicines such as ciprofloxacin [1].

Rasagiline is marketed primarily as an immediate-release oral tablet. The approved product, Azilect, contains rasagiline mesylate and conventional tablet excipients. Generic products use different inactive-ingredient systems but remain therapeutically equivalent when approved through the abbreviated new drug application pathway.

Rasagiline product profile

Attribute	Commercial relevance
Active ingredient	Rasagiline mesylate
Therapeutic class	Selective monoamine oxidase-B inhibitor
Primary indication	Parkinson's disease
Main dosage form	Immediate-release oral tablet
Strengths	0.5 mg and 1 mg
Administration	Once daily
Market structure	Brand and multiple generic products
Regulatory pathway	Small-molecule NDA and ANDA
Biosimilar relevance	None
Main formulation challenge	Accurate low-dose loading and acceptable patient administration
Main commercial constraint	Generic substitution and limited differentiation in the standard tablet

What excipients are used in rasagiline tablets?

Rasagiline tablets generally use a conventional solid oral excipient platform. Product-specific inactive ingredients differ by manufacturer and strength. The Azilect labeling identifies excipients including mannitol, corn starch, pregelatinized starch, colloidal silicon dioxide, stearic acid, and talc [1].

The formulation strategy is consistent with a low-dose immediate-release product:

• Mannitol or another soluble filler provides tablet mass.
• Corn starch and pregelatinized starch support dilution, disintegration, and compression.
• Colloidal silicon dioxide improves powder flow.
• Stearic acid supports lubrication.
• Talc may contribute to processing and anti-adherence performance.

The critical technical issue is not the absolute tablet weight. It is uniform distribution of a small quantity of rasagiline mesylate through the blend. Poor segregation control can create content-uniformity failures, especially at the 0.5 mg strength.

Key excipient attributes

Excipient function	Relevant performance attribute	Rasagiline development implication
Diluent	Low moisture variability and consistent particle size	Supports uniform low-dose blending
Binder	Adequate granule strength without slowing dissolution	Useful if direct compression is inadequate
Disintegrant	Rapid tablet breakup	Preserves immediate-release behavior
Glidant	Flow improvement at low concentration	Reduces fill-weight variation
Lubricant	Low ejection force with limited dissolution impact	Requires control of blending time
Coating system	Moisture and light protection	Can improve handling and swallowability
Taste-masking excipient	Low drug-excipient reactivity	Relevant for orally disintegrating formats

What excipient risks affect rasagiline formulation?

Rasagiline is administered at a low dose, so excipient selection must be evaluated against content uniformity, blend segregation, dissolution, and assay sensitivity. A formulation that performs well at 1 mg may not transfer directly to 0.5 mg.

Low-dose content uniformity

The principal manufacturing risk is inadequate distribution of the active ingredient. Particle-size mismatch between rasagiline mesylate and the filler can cause segregation during transfer, hopper discharge, or tablet compression. Ordered mixing, wet granulation, dry granulation, or carrier-based premixing can reduce this risk.

A commercial formulation should establish:

1. Active-to-carrier particle-size compatibility.
2. Blend uniformity after scale-up.
3. Segregation resistance during equipment transfer.
4. Tablet-to-tablet assay consistency.
5. Stability of the active-excipient mixture.

Moisture and chemical compatibility

Excipient moisture can affect powder flow, granule strength, tablet hardness, and dissolution. A development program should test hygroscopic fillers, starches, polyols, and coating systems under accelerated and long-term conditions. Compatibility screening should include assay, degradation products, dissolution, water activity, and physical changes.

Mannitol is attractive because it provides a relatively low-hygroscopicity, patient-friendly filler platform. Lactose, microcrystalline cellulose, coprocessed excipients, and alternative polyols may offer manufacturing benefits but require product-specific compatibility and performance testing.

Lubrication and dissolution

Over-lubrication can reduce tablet wettability and slow disintegration. This is relevant when stearic acid or magnesium stearate is used at higher levels or when blending time increases during scale-up. The commercial target should be rapid and reproducible immediate release rather than maximum tablet hardness.

What formulations are protected or commercially available for rasagiline?

The established product is an immediate-release tablet. The major formulation opportunity is therefore to create a differentiated dosage form rather than replicate the standard tablet.

Immediate-release tablets

The standard tablet remains the lowest-risk commercial platform. Opportunities include:

• Smaller tablet dimensions.
• Improved swallowability.
• Better scoreability or unit-dose packaging.
• Reduced excipient complexity.
• Improved low-dose content uniformity.
• Manufacturing through direct compression or continuous processing.

These changes may support formulation patents, but they usually provide limited pricing power unless they produce a measurable clinical or adherence benefit.

Orally disintegrating tablets

An orally disintegrating tablet could address patients with dysphagia, tremor, reduced dexterity, or difficulty taking tablets with water. Potential excipient systems include mannitol, crospovidone, sodium starch glycolate, low-substituted hydroxypropyl cellulose, and taste-masking polymers.

The principal obstacles are:

• Bitter or metallic taste exposure.
• Mechanical fragility.
• Moisture sensitivity.
• Dose uniformity after compression.
• Demonstration of rapid disintegration without compromising stability.

A taste-masked orally disintegrating product has a stronger commercial rationale than a simple fast-disintegrating tablet. It could support lifecycle management if the manufacturer demonstrates improved administration in a defined patient population.

Oral granules or sprinkle formulations

Granules or sprinkle products could support patients who cannot swallow tablets. This format may be administered with soft food, subject to labeling and stability requirements. Excipient choices must prevent premature dissolution, dose loss on the food matrix, and segregation of the active from the carrier.

This strategy has potential in Parkinson's disease, where motor impairment can make tablet handling difficult. The regulatory burden includes administration-method validation and evidence that food does not materially alter exposure.

Oral liquid formulations

A liquid formulation could improve dosing flexibility and administration for patients with dysphagia. It also creates substantial development risks:

• Rasagiline solubility and pH control.
• Chemical stability in aqueous media.
• Preservative compatibility.
• Dose measurement accuracy.
• Container-closure adsorption or permeation.
• Patient exposure to taste.

A concentrated oral solution or suspension may be more practical than a ready-to-use low-concentration liquid. Unit-dose packaging could reduce dosing errors but would increase packaging cost.

Extended-release and transdermal systems

Extended-release formulations are technically possible but commercially difficult because rasagiline is already administered once daily. An extended-release product would need to show an advantage in tolerability, pharmacokinetics, adherence, or combination use.

A transdermal system could create a more differentiated product, but the required drug load, skin permeation, adhesion, irritation profile, and manufacturing complexity would be substantial. The opportunity would be closer to a new drug-delivery product than a conventional excipient reformulation.

When does rasagiline lose exclusivity?

Rasagiline's original U.S. composition-of-matter protection has expired, and generic rasagiline products have been approved. The Orange Book is the principal source for listed patents, regulatory exclusivity, and approved product information [2].

Rasagiline U.S. exclusivity timeline

Event	Timing	Commercial effect
Azilect U.S. approval	2006	Originator commercial launch
Original patent protection	Expired before current generic market maturity	Removed the principal barrier to ANDA entry
Generic rasagiline approvals	Began in the late 2010s	Established generic substitution
Current market position	Mature generic market	Limits value of an unmodified tablet
Remaining opportunity	New dosage forms, combinations, delivery technologies	Requires differentiated claims and regulatory support

Patent expiry dates should be verified against the applicable Orange Book edition and patent records for the relevant product. Patent term adjustment, pediatric exclusivity, formulation patents, and jurisdiction-specific rights can alter an exact launch analysis.

What patents protect rasagiline formulations?

The original rasagiline estate included composition and pharmaceutical-use protection. Basic active-ingredient protection no longer provides a reliable barrier to ordinary tablet competition in the United States.

New commercial protection would more likely arise from:

• Orally disintegrating compositions.
• Taste-masked particles or coated granules.
• Specific excipient ratios.
• Low-dose content-uniformity processes.
• Multiparticulate delivery systems.
• Oral liquids with defined pH and stabilizer systems.
• Combination products containing rasagiline and another Parkinson's therapy.
• Patient-specific administration methods.
• Packaging systems that improve stability or dosing accuracy.

A formulation patent must provide more than a list of conventional excipients. Stronger claims would link the excipient system to a measurable result, such as improved stability, a defined dissolution profile, reduced impurity formation, improved taste, or clinically relevant administration performance.

Patent-strength assessment

Claim type	Relative strength	Main vulnerability
Rasagiline compound	Low in the U.S. after expiry	Expired basic protection
Conventional immediate-release tablet	Low to moderate	Obviousness and design-around risk
Specific ODT composition	Moderate	Prior-art combinations and enablement
Taste-masked multiparticulates	Moderate to strong if performance-linked	Reproducibility and obviousness
Oral liquid stability system	Moderate	Broad prior art in liquid dosage forms
Manufacturing process for uniform low dose	Moderate	Process evidence and infringement detection
Fixed-dose combination	Moderate to strong	Clinical and obviousness requirements
Transdermal delivery	Potentially strong	High development and regulatory risk

What is the FDA regulatory status of rasagiline?

Rasagiline is an FDA-approved small-molecule drug. Generic products can rely on the reference-listed drug through the ANDA pathway if they demonstrate pharmaceutical equivalence, bioequivalence, and compliance with applicable quality requirements [1, 2].

A new dosage form, route of administration, or clinically differentiated formulation may require a new drug application or a supplemental pathway depending on the product's relationship to the reference product and the claims being pursued. An orally disintegrating tablet that is pharmaceutically equivalent and bioequivalent may have an ANDA pathway, but a product with materially different pharmacokinetics, route, or therapeutic claims may require a more extensive submission.

Excipient regulatory considerations

FDA's inactive-ingredient database can help assess prior use of an excipient in approved drug products, but it does not eliminate the need to justify concentration, route, dosage form, and patient exposure [3]. Novel excipients may require additional toxicology and regulatory interaction.

For global commercialization, the excipient package must also address:

• Pharmacopeial status.
• Regional permitted-use limits.
• Nitrosamine and elemental-impurity controls.
• Residual solvents.
• Allergen and animal-origin statements.
• Genetically modified organism status.
• Supply continuity.
• Change-control documentation.

Which companies are challenging or competing with rasagiline?

The competitive field is composed mainly of generic manufacturers and alternative Parkinson's therapies. Generic rasagiline competition is more relevant than biosimilar competition because rasagiline is a chemically synthesized small molecule.

Competitive landscape

Segment	Products or companies	Commercial implication
Originator	Teva, following the Azilect business history	Brand recognition and clinical reference
Generics	Multiple ANDA applicants and approved suppliers	Price pressure and substitution
Adjunctive Parkinson's drugs	Safinamide, selegiline, dopamine agonists, levodopa combinations	Limits premium pricing for rasagiline innovation
Specialty delivery companies	Oral thin-film, ODT, multiparticulate, and liquid developers	Potential partners for lifecycle products
Contract manufacturers	Oral solid-dose and specialty dosage-form manufacturers	Enable lower-capital commercialization

No biosimilar development pathway applies. A competing product would be a generic, hybrid, reformulated, or combination product.

What commercial opportunities exist for rasagiline excipients?

The highest-value opportunity is a product that solves an administration problem rather than a product that merely changes the tablet filler.

Priority opportunity matrix

Opportunity	Patient value	Development risk	Commercial potential
Smaller immediate-release tablet	Low to moderate	Low	Low
Improved 0.5 mg content uniformity	Moderate	Low to moderate	Moderate for generic suppliers
Orally disintegrating tablet	Moderate to high	Moderate	Moderate to high
Taste-masked ODT	High for selected patients	Moderate to high	High if clinically differentiated
Sprinkle granules	High for dysphagia	Moderate	Moderate
Oral liquid	High for severe swallowing limitations	High	Selective
Fixed-dose combination	High if clinically justified	High	High
Extended-release tablet	Uncertain	High	Low to moderate
Transdermal system	Potentially high	Very high	Uncertain

Revenue exposure

The largest revenue exposure is associated with existing rasagiline tablet sales, but generic erosion makes public product-level revenue attribution difficult. A standard tablet strategy is likely to compete on cost, supply reliability, and regulatory execution. A premium opportunity requires a protected dosage form, a differentiated label, or a combination product.

The most defensible commercial model is one of the following:

1. License a protected ODT or taste-masking platform to a generic manufacturer.
2. Develop a differentiated product for a specialty Parkinson's portfolio.
3. Supply a validated low-dose excipient and process platform to multiple manufacturers.
4. Partner with a company that already has Parkinson's disease commercial infrastructure.
5. Pursue a fixed-dose combination with clinical and adherence data.

How can an excipient strategy create manufacturing and IP barriers?

Manufacturing protection is strongest when the excipient system is tied to a process parameter and a finished-product result. A patent covering "rasagiline plus mannitol" is vulnerable if the combination is conventional. A claim covering a defined particle-size distribution, ordered mixing sequence, lubricant concentration, blend endpoint, and content-uniformity result can be more difficult to design around.

Potential barriers include:

• Proprietary premix technology for submilligram active loading.
• Controlled particle engineering.
• Moisture-protective coating systems.
• Taste-masking layers with defined dissolution release.
• Continuous manufacturing processes.
• Unit-dose packaging with validated stability.
• Specialized equipment for fragile ODT tablets.

Trade-secret protection may be more practical than patent protection for blend order, process controls, equipment configuration, and scale-up parameters. The weakness is that process secrets can be difficult to enforce when the final product does not reveal the manufacturing method.

What generic launch risks exist for new rasagiline products?

A new product faces several launch risks despite the expiry of basic compound protection:

• ANDA applicants may challenge formulation claims under Paragraph IV.
• Conventional excipient systems may be considered obvious.
• A new dosage form may require more clinical evidence than expected.
• Taste-masking performance may not translate from laboratory testing to patient use.
• Generic substitution may limit uptake of a premium product.
• Parkinson's treatment guidelines may favor other adjunctive medicines.
• Low annual dose requirements may reduce manufacturing scale efficiencies.
• Excipient supply interruptions can affect a small-volume product disproportionately.

Paragraph IV exposure is most relevant when a new formulation patent is listed or asserted against an ANDA applicant. The practical risk depends on claim scope, Orange Book listing eligibility, patent term, prior art, and the applicant's proposed product. The existence of a formulation patent does not guarantee market exclusivity.

How does rasagiline compare with competing Parkinson's drugs?

Rasagiline has a simple once-daily administration advantage, but it competes in a crowded adjunctive-treatment market. Safinamide provides a direct comparator in the MAO-B inhibitor segment, while selegiline and multiple dopamine-based products compete for treatment sequencing and adjunctive use.

Factor	Rasagiline	Safinamide	Selegiline
Core class	MAO-B inhibitor	MAO-B inhibitor with additional pharmacology	MAO-B inhibitor
Standard administration	Once daily	Once daily	Product-dependent
Mature generic pressure	High	Lower or variable by jurisdiction	High
Formulation opportunity	ODT, liquid, sprinkle, combination	Formulation and combination strategies	Alternate dosage forms
Differentiation need	High	Moderate to high	High
Biosimilar risk	None	None	None

Rasagiline's commercial advantage is the established once-daily product and generic manufacturing base. Its disadvantage is that a new excipient platform must compete against low-cost generic tablets.

Key Takeaways

• Rasagiline is a mature small-molecule Parkinson's therapy with established generic competition.
• The basic immediate-release tablet has limited differentiation value.
• The principal formulation problem is uniform distribution of a low active dose, particularly at 0.5 mg.
• Mannitol, starch-based disintegrant systems, glidants, lubricants, and coating excipients provide a conventional platform, but each requires compatibility and dissolution control.
• ODT, taste-masked, sprinkle, and liquid products offer the clearest excipient-led opportunities.
• A premium product needs a patient-use advantage, not simply a new inactive ingredient.
• Formulation patents are more defensible when they connect excipient composition or process parameters to measurable performance.
• Rasagiline has no biosimilar pathway; competitive threats come from generics, reformulations, combinations, and alternative Parkinson's medicines.
• The strongest licensing targets are specialty dosage-form developers and generic manufacturers with Parkinson's commercial infrastructure.
• U.S. patent, Orange Book, Paragraph IV, and launch analyses must be performed against the current product-specific records before investment or litigation decisions.

FAQs

Can a new rasagiline excipient formulation receive three years of FDA exclusivity?

A reformulated product may qualify for regulatory exclusivity only if it meets the applicable statutory requirements, including submission of new clinical investigations that are essential to approval. A conventional excipient change alone generally does not create three-year exclusivity.

Is rasagiline suitable for an orally disintegrating tablet?

Yes. Its low dose and once-daily administration are technically compatible with an ODT. The main development issues are taste masking, dose uniformity, mechanical strength, moisture control, and demonstration of a meaningful administration benefit.

Can rasagiline be combined with levodopa in one tablet?

A fixed-dose combination is technically possible, but the product would require compatibility, dose-ratio, stability, dissolution, and clinical or regulatory justification. Different dosing schedules and titration needs may limit commercial practicality.

Which excipient is best for rasagiline low-dose uniformity?

No single excipient is universally best. A low-segregation carrier system with controlled particle size, suitable flow, and validated premixing generally matters more than the identity of the filler alone.

Does rasagiline have a biosimilar market?

No. Rasagiline is a synthetic small molecule. Competing products are regulated as generics, hybrid products, reformulations, or new drug products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2016). Azilect (rasagiline mesylate) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
4. U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant DNA origin.
5. National Library of Medicine. (n.d.). Rasagiline mesylate: Drug information and labeling records. DailyMed.